• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Scholar Rock Resubmits BLA for Apitegromab in SMA

    BUSINESSWIRE

    Roche Halts SMA Drug, Boosting Rivals` Prospects

    BIOSPACE

    Scholar Rock To Present At Upcoming Investor Conferences

    BUSINESSWIRE

    Scholar Rock Highlights 2026 Strategic Priorities

    BUSINESSWIRE

    Scholar Rock Presents At 44Th J.P. Morgan Healthcare Conference

    BUSINESSWIRE

    Scholar Rock Issues Employee Grants Per Nasdaq LR 5635(C)(4)

    BUSINESSWIRE

    Scholar Rock Presents At 2025 Jefferies Healthcare Conference

    BUSINESSWIRE

    Lancet Publishes Pivotal SAPPHIRE SMA Data for Apitegromab

    BUSINESSWIRE

    Scholar Rock`s Drug Helps Zepbound Patients Retain More Muscle

    REUTERS

    FDA grants priority review for Apitegromab BLA, EMA accepts MAA

    BUSINESSWIRE

    Scholar Rock Submits BLA For Apitegromab In SMA

    BUSINESSWIRE

    Scholar Rock`s phase 3 SMA trial hits goal, catapulting stock up 327%

    FIERCE PHARMA

    Scholar Rock Reports Q2 2024 Results And Business Progress

    BUSINESSWIRE

    Scholar Rock announces SRK-439 data on lean mass preservation

    BUSINESSWIRE

    Scholar Rock`s SRK-181 DRAGON Phase 1 Data At ASCO 2024

    BUSINESSWIRE

    Scholar Rock: DRAGON Trial Data On SRK-181 At ASCO 2024

    BUSINESSWIRE

    Scholar Rock Begins Obesity Phase 2, Shows SRK-439 Preclinical Data

    BUSINESSWIRE

    Scholar Rock Presents Data Demonstrating Potential Benefit of SRK-439

    BUSINESSWIRE

    Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439

    BUSINESSWIRE

    Scholar Rock Announces FDA Clearance of IND to Initiate Phase 2 with Apitegromab

    BUSINESSWIRE

    New 36-M Apitegromab Extension Data Reinforce Long-Term Substantial Improvement

    BUSINESSWIRE

    Scholar Rock to Present New Data Apitegromab at 36 Months from the Ph 2 TOPAZ

    BUSINESSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.